Cadre Holdings, Inc. (NYSE:CDRE – Get Free Report) Director Nicolas Sokolow sold 5,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $33.25, for a total value of $166,250.00. Following the completion of the sale, the director now owns 482,620 shares in the company, valued at approximately $16,047,115. This represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Nicolas Sokolow also recently made the following trade(s):
- On Monday, November 25th, Nicolas Sokolow sold 1,095 shares of Cadre stock. The shares were sold at an average price of $34.10, for a total value of $37,339.50.
Cadre Stock Down 0.3 %
Cadre stock opened at $33.44 on Thursday. The company has a market capitalization of $1.36 billion, a P/E ratio of 40.28, a PEG ratio of 1.98 and a beta of 1.30. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.96 and a current ratio of 3.01. Cadre Holdings, Inc. has a fifty-two week low of $29.18 and a fifty-two week high of $40.28. The stock has a 50-day simple moving average of $36.43 and a 200-day simple moving average of $34.96.
Cadre Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Friday, November 1st were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, November 1st. This represents a $0.35 dividend on an annualized basis and a dividend yield of 1.05%. Cadre’s payout ratio is 42.17%.
Wall Street Analysts Forecast Growth
Separately, Roth Mkm lowered their price target on Cadre from $39.00 to $37.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.
Read Our Latest Report on CDRE
Institutional Investors Weigh In On Cadre
Several hedge funds have recently made changes to their positions in CDRE. Harel Insurance Investments & Financial Services Ltd. lifted its position in Cadre by 454.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,624 shares of the company’s stock worth $55,000 after acquiring an additional 1,331 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Cadre during the second quarter worth approximately $141,000. Franklin Resources Inc. acquired a new stake in shares of Cadre during the third quarter worth $208,000. Truist Financial Corp purchased a new position in Cadre in the 2nd quarter valued at $209,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Cadre in the 2nd quarter valued at $216,000. Institutional investors and hedge funds own 43.95% of the company’s stock.
About Cadre
Cadre Holdings, Inc manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products.
Featured Stories
- Five stocks we like better than Cadre
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Market Cap Calculator: How to Calculate Market Cap
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Cadre Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadre and related companies with MarketBeat.com's FREE daily email newsletter.